f Transfer of piperaquine (PQ) into breast milk was examined in 27 Papua New Guinean women given a 3-day course of dihydroartemisinin-PQ or sulfadoxine-pyrimethamine-PQ during the second/third trimester. Breast milk was sampled on days 1, 2, 3 to 5, 7 to 11, and 14 to 17 postdelivery, a median of 70 days postdose (range, 6 to 145 days). A blood sample was taken at delivery, and additional serial samples were available from 9 women who delivered within 42 days of dosing. Milk and plasma PQ were assayed by high-performance liquid chromatography. A population-based approach was used to model the log e (plasma) and milk concentration-time data. A sigmoid E max model best described PQ breast milk transfer. The population average milk: plasma PQ ratio was 0.58, with a peak of 2.5 at delivery. The model-derived maximum milk intake (148 ml/kg of body weight/ day) was similar to the accepted value of 150 ml/kg/day. The median estimated absolute and relative cumulative infant PQ doses were 22 g and 0.07%, respectively, corresponding to absolute and relative daily doses of 0.41 g/kg and 0.004%. Model-based simulations for PQ treatment regimens given at birth, 1 week postdelivery, and 6 weeks postdelivery showed that the highest median estimated relative total infant dose (0.36%; median absolute total dose of 101 g/kg) was seen after maternal PQ treatment 6 weeks postpartum. The maximum simulated relative total and daily doses from any scenario were 4.3% and 2.5%, respectively, which were lower than the recommended 10% upper limit. Piperaquine is transferred into breast milk after maternal treatment doses, but PQ exposure for suckling infants appears safe.
Women living in areas where malaria is endemic, such as coastal Papua New Guinea (PNG), are at a high risk of malaria infection during pregnancy (1, 2). Currently recommended strategies to reduce maternal and fetal risk include prompt treatment of symptomatic malaria and intermittent presumptive treatment in pregnancy (IPTp) (3-5). Given increasing parasite resistance to the conventional therapies that have been used in pregnancy, such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), alternative regimens are needed which are safe, well tolerated, and efficacious (6). One promising candidate treatment is dihydroartemisinin-piperaquine (DHA-PQ), which has been assessed in a number of recent safety, efficacy, and pharmacokinetic studies (7-12). An alternative combination therapy for which trials have been conducted in infants as IPT is SP-PQ (13). Notwithstanding issues related to emerging SP resistance, this regimen has the advantage that the half-lives of SP are much longer than that of DHA, limiting the time between doses during which malaria parasites are exposed only to the relatively slowly eliminated PQ (14).Although available data suggest that DHA-PQ and SP-PQ in usual adult doses have no significant maternal toxicity in the second and third trimesters of pregnancy (12), there have been no published pharmacokinetic studies of the transfer of PQ into breast mil...